...

首页> 外文期刊>Intelligence: A Multidisciplinary Journal >Factors associated with prolonged post-recurrence survival in patients with postmenopausal estrogen receptor-positive breast cancer taking fulvestrant: A follow-up data of the JBCRG-C06 Safari study factors associated with prolonged post-recurrence survival in patients with postmenopausal estrogen receptor-positive breast cancer taking fulvestrant: A follow-up data of the JBCRGC-06 Safari study

【24h】

Factors associated with prolonged post-recurrence survival in patients with postmenopausal estrogen receptor-positive breast cancer taking fulvestrant: A follow-up data of the JBCRG-C06 Safari study factors associated with prolonged post-recurrence survival in patients with postmenopausal estrogen receptor-positive breast cancer taking fulvestrant: A follow-up data of the JBCRGC-06 Safari study

机译：患有氟斯特语的绝经后雌激素受体阳性乳腺癌患者长期复发后存活的因素患有富士群岛的癌症：JBCRGC-06 Safari研究的后续数据

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Intelligence: A Multidisciplinary Journal》 |2020年第2020期|共3页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心理学;
关键词

相似文献

外文文献
中文文献
专利

1. Factors associated with prolonged post-recurrence survival in patients with postmenopausal estrogen receptor-positive breast cancer taking fulvestrant: A follow-up data of the JBCRG-C06 Safari study factors associated with prolonged post-recurrence survival in patients with postmenopausal estrogen receptor-positive breast cancer taking fulvestrant: A follow-up data of the JBCRGC-06 Safari study [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：患有氟斯特语的绝经后雌激素受体阳性乳腺癌患者长期复发后存活的因素患有富士群岛的癌症：JBCRGC-06 Safari研究的后续数据
2. Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with post-menopausal estrogen receptor-positive advanced breast cancer: a sub-group analysis of the JBCRG-C06 Safari study [J] . Kawaguchi Hidetoshi, Masuda Norikazu, Nakayama Takahiro, Current medical research and opinion . 2018,第1期

机译：患有长期时间500毫克治疗失败的因素与预期绝经后雌激素受体阳性晚期乳腺癌的患者：JBCRG-C06 Safari研究的分组分析
3. Randomized Phase 2 Neoadjuvant Trial Evaluating Anastrozole and Fulvestrant Efficacy for Postmenopausal, Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Patients: Results of the UNICANCER CARMINA 02 French Trial (UCBG 0609) [J] . Lerebours Florence, Rivera Sofia, Mouret-Reynier Marie-Ange, Cancer: A Journal of the American Cancer Society . 2016,第19期

机译：评估阿那曲唑和氟来芬特对绝经后，雌激素受体阳性，人表皮生长因子受体2-阴性乳腺癌患者的疗效的随机2期新辅助试验：UNICANCER CARMINA 02法国试验（UCBG 0609）
4. Survival Prediction of Breast Cancer Patient from Gene Methylation Data with Deep LSTM Network and Ordinal Cox Model [C] . Isabelle Bichindaritz, Guanghui Liu, Christopher Bartlett International Florida Aritificial Intelligence Research Society Conference . 2020

机译：基因甲基化数据与深层LSTM网络和序数COX模型生存预测
5. Crosstalk between insulin-like growth factor 1 signaling and the estrogen receptor: Implications for breast cancer cell survival. [D] . Duong, Bich N. 2004

机译：胰岛素样生长因子1信号传导和雌激素受体之间的串扰：对乳腺癌细胞存活的影响。
6. Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized double-blind registrational trial in China [O] . Qingyuan Zhang, Zhimin Shao, Kunwei Shen, 2016

机译：雌激素受体阳性晚期乳腺癌的绝经后妇女中氟维司群500 mg vs 250 mg：在中国的一项随机双盲注册试验
7. Multicenter Observational Study of Fulvestrant 500 mg in Postmenopausal Japanese Women with Estrogen Receptor-Positive Advanced or Recurrent Breast Cancer after Prior Endocrine Treatment (SBCCSG29 Study) [O] . Kei Kimizuka, Kenichi Inoue, Shigenori E. Nagai, 2019

机译：多中心观测研究在先前内分泌治疗后雌激素受体阳性晚期或复发性乳腺癌的绝经后500毫克的多中心观测研究（SBCCSG29研究）

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号